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Abstract. Sulfoconjugates occur ubiquitously as sulfopolysaccharides, sulfolipids and sul- 
foproteins. A variety of sulfotransferases catalyze the sulfation process with 3'- 
phosphoadenosine 5'-phosphosulfate as the sulfate donor. Sulfatases that catalyze the 
desulfation of different sulfoconjugates are known to be deficient in a number of genetic storage 
disorders. 
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Introduction 
 
Numerous reviews of this subject have been published dating as far back as 1945  
(Lugg, 1945). In recent years, there has been wide-spread interest in the study of 
sulfoconjugates and their metabolism (for selected reviews, see Gregory and Robbins, 
1960; Roy, 1960a; Balasubramanian and Bachhawat, 1970; Dodgson and Rose, 1970, 
1975; Farooqui, 1980, 1981). This article deals with the more recent aspects. 
The importance of sulfur containing compounds stems from the fact that they 
participate in virtually all living processes. It is present in organisms as constituents  
of proteins, coenzymes and as major cellular metabolites like glutathione. Although  
in some cases, sulfate esters may serve no physiological role other than sulfur storage  
e.g. choline O-sulfate), the sulfated glycosaminoglycans of connective tissue or the 
sulfatides of the nervous system and most cell membranes are excellent examples of  
their structural function. Protein sulfation of tyrosine residues has been found to  
occur in most cell types in culture and in many tissues (Huttner, 1982). The recent 
discovery of a large number of secreted sulfoproteins in plasma (Hille et al., 1984)  
and neuronal axons (Stone et al., 1984) and the finding that sulfoproteins meet  
critical requirements for consideration as secretable fast-transported proteins has 
generated tremendous interest in the study of sulfate metabolism and related  
enzymes. Further, the drastic reduction in tyrosine O-sulfated proteins in rat fibro- 
blasts in culture infected with Rous sarcoma virus (Liu and Lipman, 1984) in  
contrast to the increase of tyrosine O-phosphate in a number of malignantly trans- 
formed cells are indicative of a transformation mediated change in sulfoprotein level.  
The sulfated enkephalins present in brain (Unsworth et al., 1982) may act as an  
inactive pool of enkephalins while the sulfation of neural cell adhesion molecule  
may have a role in its neurone-neurone and nerve-muscle adhesions (Sorkin et al.,  
1984). Sulfoconjugation may result in the masking of the physiological activity of  
certain compounds (e.g. steroid hormones, vitamin D, etc.) or serve as a detoxifica- 
tion mechanism (sulfoconjugation of phenols). On the other hand, the presence of 
cholesterol sulfate in the plasma membrane of spermatozoa may help in sperm capa- 
 
 
Abbreviations used: PAPS, 3'-Phosphoadeno sine 5'-phosphosulfate; Mr, molecular weight; MLD, 
metachromatic leukodystrophy. 
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citation and fertilization (Langlais et al., 1981), while the sulfation of hexosamines 
present in lutropin (Parsons and Pierci, 1980) may have a protective effect as it  
resists enzymatic deglycosylation much like the placental gonadotropins which are 
protected by peripheral sialic acids. 
The discovery of human genetic disorders of sulfate metabolism has led to a major 
boom in the research on the enzymes that are involved in the synthesis (sulfotrans- 
ferases) and degradation (Sulfo-hydrolases) of sulfated compounds. 
 
suifotransferases 
 
Sulfotransferases catalyze the transfer of sulfate from 3'-phosphoadenosine 5'-pho-
sphosulfate (active sulfate or PAPS) to a suitable acceptor containing a phenolic  
hydroxyl group. There are a variety of sulfotransferases present in animal system.  
The most widespread among them are arylsulfotransferases present in the soluble  
fraction of cell preparations where the enzymatic system responsible for the bio- 
synthesis of PAPS exists. Of the arylsulfotransferases, phenolsulfotransferase, steroid 
suifotransferase and tyrosylprotein sulfotransferase have been well studied in mamma- 
lian system. 
 
Phenolsulfotransferases 
 
The presence of phenolsulfotransferases has been demonstrated in brain, liver,  
kidney, adrenals, jejunum (Bostrom and Wengle, 1967) and platelets (Hart et al.,  
1979) of man. There are two types of phenolsulfotransferases designated the P-form 
which sulfates exogenous phenolic compounds and the M-form that sulfates endo- 
genous phenolic substances such as monoamines (Rein et al., 1982). Both forms were 
present in human brain and platelets (Young et al., 1985). The P-form of the enzyme  
may have a role to play in neutralizing dietary phenolic compounds as patients with 
dietary migraine had significantly lower levels of platelet phenol-sulfotransferase  
activity than either migrainous patients without a history of dietary provocation or  
normal controls. The P-form of the enzyme was more severely involved than the M- 
form (Littlewood et al., 1982). It is suggested that the primary function of both forms  
of phenolsulfotransferase in brain may not be connected with monoamine metabo- 
lism, but may primarily be to protect the brain from low circulating levels of poten- 
tially noxious dietary phenols (Rein et al., 1984). Recently Whittemore et al. (1985) 
purified the M-form of phenolsulfotransferase from human brain to about 20,000  
fold. The enzyme had a molecular weight (Mr) of 250,000 by gel filtration and it had  
no phenolsulfating activity. 4-Methoxytyramine was the most preferred substrate. A 
similar enzyme purified to 272-fold from human brain cortex (Yu et al., 1985) had a  
Mr of 62,000 and high affinity towards dopamine and m-tyramine. It was modera- 
tely active towards noradrenalin and p-tyramine while serotonin was a poor sub- 
strate. 
 
Steroid sulfotransferases 
 
This group of enzymes catalyze the sulfation of alcoholic hydroxyl groups. Several of 
them are known that sulfate estrone, estradiol, testosterone, androstenediol, dehy- 
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droepiandrosterone (Marcus et al., 1980), pregnenolone (Singer et al., 1980) and 
cholesterol (Lin and Horowitz, 1980). Recently, Tseng et al. (1985) have partially  
purified a human placental estrogen sulfotransferase. It had a pI of 5·8 and Mr of  
68,000 on sodium dodecyl sulphate-polyacrylamide gel electrophoresis. Even though  
the enzyme could sulfate estrone, estriol and dehydroepiandrosterone, estradiol was  
the best substrate. The effect of androgens and estrogens on rat hepatic bile acid 
sulfotransferase has been investigated by Kirkpatrick et al. (1985). The former had a 
suppressing effect while estrogens stimulated the sulfotransferase. Consequently,  
female rats had a 3-fold higher activity than males (Chen and Thaler, 1984). Similar 
effects were observed on a sulfotransferase described in rabbit uterine endometrium 
(Munakata et al., 1985). Recently, Chen and Segel (1985) purified a bile salt sulfo-
transferase from human liver to about 760-fold and showed it to be an -SH enzyme  
with a pI of 5·2 and Mr of 67,000. The sulfotransferase had no activity towards  
estrone, testosterone or phenol. 
 
Tyrosylprotein sulfotransferase 
 
Even though the presence of tyrosylprotein sulfotransferase had been demonstrated  
as early as 1966 (Banerjee and Roy, 1966), the real interest was awakened only  
recently when Huttner (1982) demonstrated the protein sulfation on tyrosine residues  
of virtually all cell lines and tissues. This was followed up by a large number of 
investigators unraveling the secretory nature of most sulfoproteins. A tyrosylprotein 
sulfotransferase has been described by Lee and Huttner (1985) in the Golgi mem- 
brane fraction of a bovine adrenal medulla homogenate. The enzyme could sulfate 
tyrosine residues of tubulin in the presence of a nonionic detergent. A polymer,  
(glutamyl, alanyl, tyrosinyl) served as a high affinity substrate. A similar enzyme has  
been described by Vargas et al. (1985) in a crude microsomal fraction from rat  
cerebral cortex. Various cholecystokinin fragments or derivatives could act as sulfate 
acceptors. Peptides with an N-terminal tyrosine residue (e.g. enkephalins or CCK-7)  
were not sulfated. The importance of these sulfoproteins are yet to be worked out.  
Other than as secretory proteins, they may be involved in the overall function of the 
protein in an identical manner as phosphoproteins. 
Sulfotransferases such as choline sulfotransferases are involved in the sulfation of 
choline, dimethylaminoethanol and dimethylethylaminoethanol (Fitzgerald, 1973;  
Kaji and Gregory, 1959; Nissen and Benson, 1961). There are sulfotransferases that 
sulfate aromatic amines such as aniline or 2-naphthylamine (Roy, 1960b). In rat 
hepatocytes sulfation of the phenolic hydroxyl group of iodothyronines facilitate the 
deiodination of these compounds (Otten et al., 1983). Sulfolipid sulfotransferases are 
present in the brain (Mckhann et al., 1965; Balasubramanian and Bachhawat, 1965; 
Cumar et al., 1968), kidney (Fleischer and Smigel, 1978) and testes where it is  
involved in spermatogenesis (Lingwood, 1985). The rat kidney galactocerebroside 
sulfotransferase has been purified to apparent homogeneity. It was hydrophobic in  
nature with a Mr of 64,000 and pI of 5·1 with essential arginine residues at the active  
site (Tennekoon et al., 1985). 
Different sulfotransferases are present for the sulfation of glycosaminoglycans  
resulting in the formation of chondroitin 4- and 6-sulfates, heparan sulfate (Suzuki et  
al., 1961) and dermatan sulfate (Hasegawa et al., 1961). Balasubramanian and  
Bachhawat (1964) demonstrated the presence of a mucopolysaccharide sulfotrans-
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ferase in rat brain cytosol that could sulfate a variety of substrates. Habuchi and  
Miyashita (1982) separated chondroitin 4- and 6-sulfotransferase from 14-day old  
chick embryos by gel filtration and showed that addition of polyamines and basic  
proteins to the incubation medium had an activating effect on both transferases. 
Investigations by various workers (Young, 1973; Richmond et al., 1972, 1973; 
DeLuca et al., 1973) have localized the glycosaminoglycan sulfotransferases on the  
Golgi and concluded that sulfating enzymes were located together with polymerizing 
enzymes in an enzyme complex so that sulfation of the heteropolysaccharide chain 
proceeded during or immediately following polymerization. Two keratan sulfotrans-
ferases have been partially purified from isolated bovine corneal cells and shown to  
have a Mr each of 220,000 and 140,000, respectively. The preparation did not show  
any chondroitin sulfotransferase activity and both enzymes acted in a co-operative  
manner on keratan sulfate fragments, which was the best preferred substrate (Rueter  
and Kresse, 1984). Evidence for the recognition of the N-acetylgalactosamine resi- 
dues in the non-reducing terminal regions of oligosaccharides by the transferases was 
revealed by Delfert and Conrad (1985) while working with microsomal preparations  
from cultured chick embryo chondrocytes which showed a high rate of sulfation at  
the reducing ends of shorter oligosaccharides, but decreased with increasing chain  
length. 
On the whole, sulfotransferases are involved in the synthesis of all the biologically 
occurring sulfoconjugates and thus participate in the overall functioning of the  
system. 
 
Sulfohydrolases 
 
The class of enzymes that hydrolyze esters of sulfate and related sulfoconjugates are 
collectively called sulfohydrolases or sulfatases. The role of sulfatases is profound in 
maintaining the concentrations of various sulfoconjugates in physiological fluids or  
the turnover of sulfated compounds in tissues, in cell-mediated cytolysis or in the 
breakdown of dietary sulfate esters. If the recent developments in the study of  
sulfated cell surface glycosaminoglycans (Wieland, 1982; Dietrich, 1984; Hook et al., 
1984) are any indication, sulfohydrolases have a very important role to play in cell  
growth and cell division. 
Sulfatases may be generally classified into alkyl, aryl and carbohydrate sulfatases. 
 
Alkylsulfatases 
 
Sulfatases that hydrolyze the sulfate esters of simple alcohols such as methanol,  
ethanol, etc. are termed as alkylsufatases. Although the formation of alkylsulfate  
esters in mammalian tissues is well known (Vestermark and Bostrom, 1959; Spencer, 
1960), the corresponding hydrolases have not been described so far except a choline 
sulfatase in higher fungi and some bacteria. 
Steroid alkylsulfatases such as dehydroepiandrosterone sulfatase, a microsomal 
enzyme rich in placenta and testes (French and Warren, 1967) are widely known. 
Sulfatases that hydrolyze sulfate esters of estrone, pregnenolone, testosterone, cho- 
lesterol and p-nitrophenol have been described in rat brain (Iwamori et al., 1976a,b). 
Recently, Milewich et al. (1984) demonstrated the presence of steroid sulfatase in  
more than 30 different tissues from mice. 
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Steroid sulfatase is involved in the mechanism of sperm capacitation and ovum 
penetration (Langlais et al., 1981). Studies by Ropers and Wieberg (1982) suggested  
that the steroid sulfatase activity in cultured cells of wood lemming is directly corre- 
lated to the number of X-chromosomes and that the sulfatase gene is also X-linked  
and not subject to inactivation while in mice the steroid sulfatase gene is subject to  
the normal pattern of X-inactivation (Crocker and Craig, 1983). 
The insoluble nature of steroid sulfatase had hampered attempts at purification  
until Noel et al. (1983) and Burns (1983) purified the enzyme 100- and 300-fold, 
respectively from human placental microsomes. The preparation obtained by Noel et 
 al. (1983) was heterogeneous in nature and it could hydrolyze sulfate esters of 
cholesterol, dehydroepiandrosterone and p-nitrophenol while the sulfatase purified  
by Burns was homogeneous and hydrolyzed dehydroepiandrosterone sulfate and p-
nitrophenylsulfate. Both preparations exhibited a Mr range of 72-74,000 daltons. 
There is evidence to suggest that different sulfatases are responsible for the hydro-
lysis of the sulfate esters of estrone, dehydroepiandrosterone, cholesterol and p-
nitrophenol (Eto et al., 1974; Mathew and Balasubramanian, 1982; Milewich and  
Garcia, 1985; Prost et al., 1985). Further Simard et al. (1985) have separated steroid 
sulfatase and arylsulfatase C (4-methylumbelliferyl or p-nitrophenylsulfatase) by  
cellogel electrophoresis and demonstrated that they are immunologically different. It  
is possible that steroid sulfatase could hydrolyze the artificial substrates of  
arylsulfatase C and not vice versa (Horwitz et al., 1986; Simard et al., 1985). Steroid 
sulfatase is stimulated by phosphatidylcholine (McNaught and France, 1980). The 
significantly lower level of this lipid in steroid sulfatase deficient placenta (McKee  
and France, 1983) suggest that phosphatidylcholine may have a role to play in  
Steroid sulfatase activity. 
 
Arylsulfatases 
 
Arylsulfatases are the most widely distributed of all the sulfohydrolases. The aryl-
sulfatase present in natural killer cells are involved in the lysis of the target cell 
membrane (Zucker-Franklin et al., 1983). They are classified into arylsulfatase A, B  
and C. The first two are soluble lysosomal enzymes and they are inhibited by pho- 
sphate and sulfate while arylsulfatase C is an insoluble microsomal enzyme which is  
not affected by phosphate or sulfate. Many of the arylsulfatases have been purified  
and identified (table 1). 
 
Arylsulfatase Α: Arylsulfatase A is perhaps the best studied of all the arylsulfatases.  
It has been purified from a variety of sources by a large number of workers (Hess,  
1983; Waheed and Van Etten, 1985a; Laidler et al., 1985; Nakamura et al., 1984). 
Sulfatase A is an acidic glycoprotein (Balasubramanian and Bachhawat, 1975) with a  
pI of 4·6–4·8 (Eto et al., 1974). It has a monomeric Mr of 102,000–107,000 and a 
carbohydrate content of 15–25%. The enzyme is rich in proline, aspartic and gluta- 
mic acids and hydrolyzes sulfate esters such as cerebroside 3-sulfate, seminolipid, 
psychosine sulfate, ascorbic acid 2-sulfate and tyrosine O-sulfate (Farooqui, 1980). 
The arylsulfatase A purified from human liver (James and Austin, 1979) contained 
two subunits of Mr 69,000 and 57,000 which on further studies proved similar sugge-
sting that the smaller subunits might have been derived from the larger one. 
 However, an arylsulfatase A purified from human urine (Laidler et al., 1985) 
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exhibited peptide subunits of 63,500 and 54,500 daltons. The subunits were immu-
nologically similar and their nonidentity is attributed to differing extents of glycosy- 
lation (Waheed et al., 1983). The enzyme was both phosphorylated and sulfated  
(Waheed and Van Etten, 1985b) and had essential arginine residues (James, 1979). It 
exhibits abnormal kinetics and the activity is linear only upto 10–15 min due to a 
substrate induced inactivation of the enzyme, which is accompanied by the binding  
of a sulfate ion from the substrate (Prosser and Roy, 1980; Waheed and Van Etten,  
1980) followed by reactivation by sulfate in the presence of the substrate. Roy (1985) 
described arylsulfatase A as a hysteretic enzyme and proposed a progress curve for  
the reaction catalyzed by the enzyme. 
An atypical arylsulfatase purified from chicken brain (Farooqui and Bachhawat,  
1972) hydrolyzed cerebroside 3-sulfate, but had properties of both arylsulfatase A  
and B. The possibility of a single enzyme hydrolyzing the substrates of both aryl- 
sulfatase A and Β cannot be ruled out as only a single arylsulfatase was present in  
chicken brain (Mathew and Balasubramanian, 1984). 
Das and Bishayee (1980) separated sheep brain arylsulfatase A into high and low-
uptake forms. The former was susceptible to alkaline phosphatase indicating the  
presence of phosphate residues. The enzyme purified from human liver exhibited 
molecular heterogeneity (Sarafian et al., 1984). Sialic acid residues were partly respo-
nsible as neuraminidase treatment could bring down the heteromer bands to only 3. 
Similar studies in lung tumors (Nakamura et al., 1984) and bladder cancer patients 
(Mitsuhashi et al., 1984) suggest an increased level of microheterogeneity of aryl- 
sulfatase A in transformed tissues. Recently, (Waheed and Van Etten, 1985b) demon-
strated the variations in carbohydrate content of arylsulfatase A in normal and  
carcinoma cell lines and concluded that the carbohydrate free enzymes were essen- 
tially similar with a Mr of 59,000 daltons and attributed this to an elevated level of 
glucosyltransferase. 
 
Arylsulfatase Β: Arylsulfatase Β is similar to arylsulfatase A in being a soluble  
lysosomal glycoprotein exhibiting molecular heterogeneity (J. Mathew and  
A. S. Balasubramanian, unpublished results). It is cationic in nature and has been  
purified from a variety of sources (Agogbua and Wynn, 1976; Farooqui and Roy,  
1976; McGovern et al., 1982; Weller and Austen, 1983). Multiple forms of arylsulfa- 
tase Β has been reported from ox tissues (Bleszynski et al., 1969), human placenta  
(Gniot-Szulzycka, 1972), human brain and liver (Harzer et al., 1973) which can be 
separated by chromatographic and electrophoretic methods. The nature and signifi- 
cance of these multiple forms are not clear at present even though sialic acid (Harris  
et al., 1982), phosphate residues (Uehara et al., 1983) and varying carbohydrate  
content have been implicated (Farooqui and Roy, 1976). 
Sulfatase Β from ox liver and brain is shown to be rich in proline and basic ami-
noacids. The enzyme has large amounts of tyrosine and an essential histione residue  
in its active site. The ability of arylsulfatase Β to hydrolyze UDP-N- 
acetylgalactosamine 4-sulfate was first demonstrated by Fluharty et al. (1975) and  
later confirmed by using homogeneous preparations of arylsulfatase Β (Farooqui,  
1976). The enzyme could also hydrolyze glucosamine 4,6-disulfate, but not glucos- 
amine 6-sulfate. 
A minor anionic form of arylsulfatase Β present in significant amounts only in  
brain, but not in other tissues like liver, kidney, testes and placenta was isolated by 
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Stevens et al. (1977). The anionic nature of the enzyme is due to its phosphoprotein 
nature (J. Mathew and A. S. Balasubramanian, unpublished results). The anionic Β 
purified from monkey brain had a Mr of 30,000 and a phosphate content of about  
7·0 mol of inorganic phosphorus per mol of protein (Lakshmi and Balasubramanian, 
1984). 
Arylsulfatase Β is located on chromosome 5 as compared to chromosome 22 of 
arylsulfatase A and the fact that each enzyme is expressed independently provides 
evidence against any common structural feature between the two enzymes (DeLuca  
et al., 1979). 
Cancer associated modification of arylsulfatase Β has been reported in lung  
tumors (Gasa et al., 1981) which is speculated to be due to transformation mediated 
elevation of sialyltransferase and protein kinase (Niinobe et al., 1979; Kottgen et al., 
1978) resulting in the phosphorylation of arylsulfatase Β both on its protein and 
carbohydrate moiety (Gasa and Makita, 1983). Human brain anionic Β was taken up 
rapidly by multiple sulfatase deficient fibroblasts whereas arylsulfatase Β was pra- 
ctically not taken up into the cells. Alkaline phosphatase treatment could abolish this 
high-uptake activity without diminishing its catalytic activity (Kureha and Eto,  
1983). 
Steckel et al. (1983) showed that arylsulfatase Β synthesized and secreted as a  
64,000 Mr precursor was processed to a 62,000 dalton intermediate and mature  
forms of Mr 47,000, 40,000 and 31,000 daltons. The processing of 62,000 Mr inter- 
mediate to the pair with Mr 40,000 and 31,000 depended on cysteine proteinases  
(Steckel et al., 1985). 
 
Arylsulfatase C: The presence of arylsulfatase C was first demonstrated by  
Dodgson et al. (1954) in rat liver microsomes and later in various human tissues 
(Dodgson et al., 1956). The enzyme is located in the endoplasmic reticulum and the 
nuclear outer membrane (Zemelman et al., 1985). The numerous similarities obser- 
ved between mammalian arylsulfatase C and steroid sulfatase had led to the hypo- 
thesis that a single enzyme is responsible for both activities (Dolly et al., 1972; 
Balasubramanian, 1976; Iwamori et al., 1976b). The chaotropically solubilized 
arylsulfatase C from monkey brain has been shown to require a dialyzable activator  
which had no effect on the estrone sulfatase activity from the same source (Lakshmi  
and Balasubramanian, 1979). This led to the possibility of separate enzymes respon- 
sible for the hydrolysis of p-nitrophenylsulfate and estrone sulfate. Making use of the 
hydrophobic nature of arylsulfatase C, it could be partially separated from estrone 
sulfatase by hydrophobic interaction chromatography (Mathew and Balasubramanian, 
1982). 
Persistent attempts by workers to purify arylsulfatase C were unsuccessful until 
Moriyasu et al. (1982) obtained a homogeneous preparation from rat liver micro- 
somes. The native enzyme had a Mr of 280,000 by gel filtration while the monomeric  
Mr was 72,000. It was a glycoprotein with a pI of 8·1. The carbohydrate part of the 
enzyme was rich in mannose and N-acetylglucosamine. It is not know whether  
steroid sulfatase activity is associated with this preparation. 
The physiological substrate of arylsulfatase C is not known. The enzyme purified  
from placenta (Noel et al., 1983; Burns, 1983) has steroid sulfatase activity Arylsulfa- 
tase C purified from human skin fibroblasts (Simard et al., 1985) exhibited/two 
immunologically different bands on cellogel electrophoresis. Both forms hydrolyzed 
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the artificial substrate 4-methylumbelliferylsulfate, while only the slow form showed  
any steroid sulfatase activity. Hence it is possible that the fast form is the 'true 
arylsulfatase C while the slow form is steroid sulfatase. 
 
Carbohydrate sulfatases 
 
A large number of carbohydrate sulfate esters such as lactose 6-sulfate, sulfated gly-
cosaminoglycans, ascorbic acid 2-sulfate, N-acetylglucosamine 6-sulfate, cellulose 
polysulfate, etc. are known at present and the sulfatases that hydrolyze the sulfate  
part of these compounds are collectively referred to as glycosulfatases or carbo- 
hydrate sulfatases. The enzyme is present in mollusks, bacteria and molds (Dodgson  
and Rose, 1975): Habuchi et al. (1979) have identified 5 glycosaminoglycan sulfatases 
from rat skin. They are N-acetylglucosamine and N-acetylgalactosamine 6-sulfate 
sulfatase, N-acetylgalactosamine 4-sulfate sulfatase, heparan sulfate N-sulfatase and 
iduronate sulfatase. The deficiency of any one of these may give rise to a specific  
storage disorder. Iduronate sulfatase has been purified from human liver to 80-fold  
and shown to be of heterogeneous nature. It had a pH optimum of 4·0 and was free  
of other sulfatases (Yutaka et al., 1982). 
Recently, Benitez and Halver (1982) purified an ascorbic acid 2-sulfatase from  
rainbow trout. It had a Mr of 117,500 and a pH optimum of 6·0 and was structu- 
rally identical to human arylsulfatase A. Placental N-acetylgalactosamine 6-sulfate 
sulfatase has been purified by Glossl et al. (1979) and shown it to be a glycoprotein  
of Mr 100,000 by gel filtration. It had a monomeric Mr of 78,000. A similar enzyme,  
N-acetylglucosamine 6-sulfate sulfatase has been purified from human urine and  
shown to be a glycoprotein of Mr 97,000 with a pH optimum of 5·5. It is also active 
towards glucose 6-sulfate (Basner et al., 1979a). On the other hand, heparan sulfate  
N-sulfatase, a lysosomal enzyme purified from human urine had a pH optimum of  
4·5, pI of 4·7 and a Mr of 120,000 (Friedman and Arsenis, 1972, 1974). 
 
Genetic disorders of sulfate metabolism 
 
The genetic disorders of sulfate metabolism are characterized by the abnormal accu-
mulation and excretion of different metabolites corresponding to the type of defect  
(table 2). The accumulation of these compounds have been demonstrated in liver,  
kidney and brain. Mental retardation is invariably associated with many of these 
disorders. 
 
Metachromatic leukodystrophy or arylsulfatase A deficiency 
 
The physiological substrate of arylsulfatase A, cerebroside 3-sulfate accumulates in  
brain, peripheral nerve, kidney and other visceral organs of the patient as a result of  
this genetic disorder. It is an autosomal recessive disorder classified into late in- 
fantile, juvenile and adult disorders. The first demonstration of arylsulfatase A defi- 
ciency in metachromatic leukodystrophy (MLD) came from the work of Austin et al. 
(1963). Diagnosis is carried out by measuring the urinary excretion of cerebroside 3- 
sulfate, presence of metachromatic deposits in sural nerve and by the deficiency of 
arylsulfatase A in urine, leukocytes or skin fibroblasts (Brady, 1978). Several studies 
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have shown that MLD patients have a mutated sulfatase A which is immunologi- 
cally cross-reactive with monospecific antibody, but had very little enzyme activity 
(Neuwelt et al., 1973; Shapira and Nadler, 1975). 
There is marked demyelination in the nervous system of patients suffering from  
MLD. Recent studies have demonstrated pseudoarylsulfatase A deficiency in fibro- 
blasts from healthy individuals (Chang and Davidson, 1983). The enzyme was  
similar to normal arylsulfatase A except for a slight differences in pI value. Low 
arylsulfatase A activity has been reported in leukocytes and skin fibroblasts of  
healthy members of families having an MLD patient (Dubois et al., 1977; Butterworth  
et al., 1978). In the late infantile form of MLD, sulfatase A is deficient in brain, liver  
and spleen (Yamaguchi et al., 1975). 
 
Maroteaux-Lamy syndrome (arylsulfatase Β deficiency) 
 
Arylsulfatase Β deficiency is characterized by severe skeleletal deformities, gross  
corneal opacity, hepatosplenomegaly, growth retardation and increased urinary  
excretion of dermatan sulfate as N-acetylgalactosamine 4-sulfate residues of  
dermatan sulfate are the physiological substrate of the enzyme. Recent studies  
(Gasper et al., 1984) have indicated that allogenic bone marrow transplant from a 
histocompatible donor could reverse an advanced state of arylsulfatase Β deficiency  
in a two year old Siamese cat as evidenced by a normalization of urinary glycos-
aminoglycan excretion, leukocyte arylsulfatase Β activity and sustained improve- 
ment in clinical symptoms. Hence it would be only a question of time before man  
can be treated in a similar manner. 
 
Hunter's syndrome (iduronate sulfate sulfatase deficiency) 
 
It is a sex-linked recessive trait characterized by abnormal accumulation of heparan 
sulfate, dermatan sulfate and by the deficiency of L-iduronate sulfate sulfatase. It is 
known to occur only in hemizygous males, while the females who are heterozygous  
are probably protected from the disorder by an enzyme transfer from normal to  
abnormal cells. The syndrome can be diagnosed by assaying iduronate sulfate sul- 
fatase activity in serum, lymphocytes, fibroblasts and hair roots (Liebaers and  
Neufeld, 1976; Migeon et al., 1977; Yutaka et al., 1978). 
 
Morquio's syndrome 
 
This syndrome is characterized by abnormal accumulation and excretion of keratan 
sulfate and chondroitin 6-sulfate and distinguishable from others by such characteri- 
stic clinical features as disproportionate dwarfism, spondiloepiphyseal dysplasia,  
dental anomalies, corneal clouding but normal intellect. Patients are deficient in N-
acetylgalactosamine 6-sulfate sulfatase (Singh et al., 1976) and galactose 6-sulfate 
sulfatase (Yutaka et al., 1982). 
 
Sanfilippo 's syndrome type A (heparan sulfate Ν-sulfatase deficiency) 
 
Patients with this syndrome suffer from severe neurological symptoms but mild 
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physical alterations. It can be diagnosed by assaying heparan sulfate N-sulfatase in 
fibroblasts and peripheral leukocytes (Schmidt et al., 1977). 
 
Placental steroid sulfatase deficiency 
 
Steroid sulfatase and arylsulfatase C (p-nitrophenylsulfatase) are absent in the  
placenta of pregnant women having this deficiency syndrome. It is characterized by  
low urinary estrogen excretion compared to normal and pregnant women. This  
disorder can be easily distinguished from other sulfatase deficiencies both by being  
sex-linked and causing pregnancy complications (Oakey, 1978). The babies are  
usually males and develop an ichthyotic skin condition probably caused by excessive 
accumulation of cholesterol sulfate in the pathological scale (Williams and Elias,  
1981) in the first year. Corneal dystrophy has been described in patients with X- 
linked ichthyosis and some female carriers (Sever et al., 1968). 
Recent studies have shown that steroid sulfatase deficient placental microsomes  
have a significantly lower percentage of phosphatidylcholine as compared to normal 
placental microsomes (McKee and France, 1983). This finding is important espe- 
cially since phosphatidylcholine can stimulate steroid sulfatase (McNaught and  
France, 1980). The disorder can be diagnosed by subjecting the patients to dehydro-
epiandrosterone and dehydroepiandrosterone sulfate loading tests (Braunstein et al.,  
1976) or by measuring the cholesterol sulfate content in the pathological scales  
(William and Elias, 1981). 
 
Multiple sulfatase deficiency 
 
It is an autosomal recessive trait characterized by a profound deficiency of aryl- 
sulfatase C along with arylsulfatase Α, Β and steroid sulfatase resulting in the accu-
mulation of cerebroside 3-sulfate, steroid sulfates and mucopolysaccharides (Eto et  
al., 1974; Murphy et al., 1971; Austin, 1973). The suggestion that the deficient aryl-
sulfatases must be having a common subunit controlled by a single gene (Moser et  
al., 1972) has been ruled out by the fact that arylsulfatase A and Β are assigned to 
different chromosomes (DeLuca et al., 1979; Hors-Cayla et al., 1979). Nine different 
sulfatases (arylsulfatase Α, Β and C, cholesterol sulfatase, dehydroepiandrosterone 
sulfatase, iduronate 2-sulfate sulfatase, N-acetylgalactosamine 6-sulfatase, N-acetyl-
glucosamine 6-sulfate sulfatase and heparan sulfate N-sulfatase) are shown to be  
deficient in this syndrome (Banser et al., 1979b). Studies by Chang et al. (1983) using 
cultured fibroblasts from 7 different patients have suggested typing of the patients  
into 3 groups: (i) deficient in Α, Β and C; (ii) deficient in A and C with half or  
near normal levels of Β and (iii) same as in (ii), but arylsulfatase A activity bands are 
detectable. 
Recent studies using fibroblasts from multiple sulfatase deficient patients demon-
strate a decreased stability of arylsulfatase A and the 47,000 dalton form of aryl- 
sulfatase Β (Steckel et al., 1985) and steroid sulfatase (Horwitz et al., 1986). The root 
cause of this disorder is still not known. They are probably secondary manifestations  
of an yet unknown primary genetic defect. 
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